• No results found

University of Groningen Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant Lederhofer, Julia

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant Lederhofer, Julia"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant

Lederhofer, Julia

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Lederhofer, J. (2018). Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant: A vaccine candidate for the elderly and pregnant women. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Stellingen

1. The main challenge for the development of a vaccine against Respiratory Syncytial virus (RSV) infection remains that such a vaccine needs to provide better protection than a natural RSV infection.

2. The addition of an adjuvant is crucial for a vaccine against RSV for the elderly or pregnant women. (this thesis)

3. The synthetic version of monophosphoryl lipid A (MPLA), 3D-PHAD®, is an excellent replacement for natural, LPS-derived, MPLA as a potential adjuvant in a virosomal or proteoliposomal RSV vaccine. (this thesis)

4. Proteoliposomes form an attractive alternative to virosomes for use in a future RSV vaccine. (this thesis)

5. Over the last several years vaccination coverage of newborns, toddlers and schoolchildren has been declining. This is extremely worrying. Therefore, it is of utmost importance to educate parents to get their children vaccinated. 6. The emerging Nipah virus may well be the cause of a major outbreak in

near future. It infects a wide range of animals and causes severe disease and death in humans. Currently, there are no vaccines available against this emerging virus. (WHO)

7. The haemagglutinin of Influenza virus is well characterized and currently used as the main antigen in flu vaccines. However, to design a universal vaccine, researchers should also devote attention to Neuraminidase, the other surface glycoprotein, which has been neglected for a long time in vaccine development. (Eichelberger et al., 2018, Aug; 53:38-44, Current Opinion in Immunology)

8. It is through science that we prove, but through intuition that we discover. (Henri Poincare)

9. When all the details fit perfectly, something is probably wrong with the story. (Charles Baxter, Burning down the house: Essays on Fiction)

Referenties

GERELATEERDE DOCUMENTEN

Toward a virosomal respiratory syncytial virus vaccine with a built-in lipophilic adjuvant: A vaccine candidate for the elderly and pregnant women..

Evaluation of an Intranasal Virosomal Vaccine against Respiratory Syncytial Virus in Mice: Effect of TLR2 and NOD2 Ligands on Induction of Systemic and Mucosal Immune

In line with the above data, mice immunized with RSV-MPLA virosomes showed significantly increased IFNγ levels in their lungs upon live virus challenge when compared to

Virosome-incorporated MPLA variants also stimulated antibody secretion and isotype switching to IgG2a antibody production in splenic B cells, particularly when supernatants were

In conclusion, less toxic variants of MPLA, like 3-OD-MPLA and the synthetic 3D-PHAD® in RSV virosomes have the capacity to boost protective antibody responses upon immunization

Briefly, purified RSV virus was solubilized with DCPC, the viral nucleocapsid was removed by ultracentrifugation, the supernatant was added to a dry lipid film consisting of

Antibodies specific for the preF conformation were detected in sera from mice immunized with the virosomal vaccine, irrespective of the strain it was derived from (Figure

In line with these findings, we found that preF or postF- 3D-PHAD®-proteoliposomes induced higher preF- and postF-specific IgG antibody levels compared to levels induced